Fiera Capital Corp Purchases 5,993 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Fiera Capital Corp lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 1.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 444,330 shares of the company’s stock after buying an additional 5,993 shares during the period. Fiera Capital Corp’s holdings in Crinetics Pharmaceuticals were worth $12,779,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MetLife Investment Management LLC boosted its stake in Crinetics Pharmaceuticals by 0.7% in the first quarter. MetLife Investment Management LLC now owns 53,414 shares of the company’s stock valued at $1,792,000 after acquiring an additional 394 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Crinetics Pharmaceuticals by 1.8% during the 1st quarter. Arizona State Retirement System now owns 23,899 shares of the company’s stock valued at $802,000 after purchasing an additional 430 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Crinetics Pharmaceuticals by 16.2% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,619 shares of the company’s stock valued at $104,000 after purchasing an additional 505 shares during the last quarter. Xponance Inc. boosted its position in shares of Crinetics Pharmaceuticals by 9.1% in the 1st quarter. Xponance Inc. now owns 6,857 shares of the company’s stock worth $230,000 after purchasing an additional 573 shares in the last quarter. Finally, Assetmark Inc. grew its stake in Crinetics Pharmaceuticals by 3.3% during the 2nd quarter. Assetmark Inc. now owns 18,667 shares of the company’s stock worth $537,000 after buying an additional 603 shares during the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. JMP Securities increased their price target on Crinetics Pharmaceuticals from $86.00 to $143.00 and gave the company a “market outperform” rating in a research note on Friday, September 26th. Morgan Stanley increased their price objective on shares of Crinetics Pharmaceuticals from $65.00 to $77.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. The Goldman Sachs Group boosted their target price on shares of Crinetics Pharmaceuticals from $35.00 to $40.00 and gave the stock a “neutral” rating in a research report on Friday, September 26th. Oppenheimer upped their price target on shares of Crinetics Pharmaceuticals from $73.00 to $87.00 and gave the company an “outperform” rating in a research note on Tuesday, September 30th. Finally, Citizens Jmp lowered their price objective on shares of Crinetics Pharmaceuticals from $143.00 to $108.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Crinetics Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $77.55.

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Dana Pizzuti sold 30,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $30.43, for a total value of $912,900.00. Following the completion of the transaction, the insider owned 66,270 shares of the company’s stock, valued at $2,016,596.10. The trade was a 31.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Richard Scott Struthers sold 4,000 shares of the business’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $45.00, for a total value of $180,000.00. Following the completion of the transaction, the chief executive officer directly owned 106,000 shares of the company’s stock, valued at approximately $4,770,000. This trade represents a 3.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 66,492 shares of company stock worth $2,420,687 over the last three months. Company insiders own 4.60% of the company’s stock.

Crinetics Pharmaceuticals Trading Down 3.2%

Shares of NASDAQ:CRNX opened at $41.43 on Friday. Crinetics Pharmaceuticals, Inc. has a twelve month low of $24.10 and a twelve month high of $62.53. The company has a market cap of $3.93 billion, a PE ratio of -9.15 and a beta of 0.25. The company’s 50 day moving average is $40.32 and its 200 day moving average is $34.12.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.11). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.39 million. During the same quarter in the prior year, the business earned ($0.96) earnings per share. Equities research analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.